CD276 and neoplasm: B7-H3 represents a promising target for the treatment of RMS, because it not only appears as one of the most upregulated cell surface antigens in tumors but, also, its immunoregulatory function may provide novel insights on the mechanisms associated with tumor immune evasion for the development of new immune checkpoint inhibitors.